El eculizumab (Soliris®) para el tratamiento de la hemoglobinuria paroxística nocturna

Categoría Resumen estructurado de revisiones sistemáticas
RevistaHTA Database
Año 2012
RECORD STATUS: This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. CITATION: All Wales Medicines Strategy Group (AWMSG). Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0509. 2009
Epistemonikos ID: c73b04152624fb217001b94cfad1b4259002ab91
First added on: Feb 06, 2015